BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Germany-based biotechnology firm BioNTech SE (BNTX) on Thursday said that it intends to acquire its peer CureVac (CVAC) in an ...

However, looming over the scientific excitement are concerns about proposed U.S. budget cuts, including a potential 40% ...

BioNTech's $1.25 billion acquisition of CureVac creates a "German biotech champion" focused on mRNA-based cancer treatments, with CureVac shares surging 38% on the announcement.

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Shares of Kazia Therapeutics surged after the company published data it said underscores the potential of its lead asset to treat certain types of breast cancer. The stock jumped 79%, to $9.43, in ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Inspired by advances in cancer therapy, a team at the Buck Institute has engineered immune cells equipped with specialized ...